New Research Study Demonstrates Increased Acceptance Among Healthcare Providers
Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com
Expanded Coverage with recent New York Medicaid Approval
SOLANA BEACH, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced positive outcomes from an additional research study conducted for GIMOTI® (metoclopramide) nasal spray. The study’s objective was to assess the overall awareness of and familiarity with GIMOTI across a broad spectrum of healthcare providers. The company also announced the availability of recently recorded patient testimonial videos and a recent positive insurer decision for New York State Medicaid.
Research Study
In December 2021, Evoke’s commercialization partner EVERSANA conducted a GIMOTI Awareness, Trial, and Usage (ATU) Study to gauge continued physician and provider awareness, trial, and utilization of GIMOTI following market developments in the second half of 2021. Similar to previous studies, this survey was divided into four sections: the current treatment approach, recent prescribing behavior, treatment awareness, and additional perspectives around support resources.
The survey participant population of 135 respondents was comprised of 65 gastroenterologists (GIs) targeted by Evoke sales professionals, 25 non-target GIs, 25 non-target primary care physicians (PCP), and 20 non-target GI-affiliated nurse practitioners (NPs) and physician assistants (PAs).
Key findings from the survey include:
- Steady increase in intent to prescribe GIMOTI
- 88% of all respondents intend to prescribe GIMOTI
- 92% of targeted GIs compared to 90% in previous study
- 92% of non-targeted GIs compared to 86% in previous wave
- 80% of PCPs compared to 100% in previous study
- 89% of NP/PAs; increased sample size since previous study
- 88% of all respondents intend to prescribe GIMOTI
- Increase in proportion of patients using GIMOTI in any line of therapy
- Wider acceptance especially among GIs as first-line usage for patients with severe gastroparesis
- Greater usage of GIMOTI as third-line therapy showing significant increase by GIs of 33.3% from previous waves
- Scored higher familiarity rates among all GIs and NPs/PAs; over 80% of target and non-target GI respondents show robust awareness of GIMOTI
- Respondents across all segments perceive an oral tablet as the least effective route of administration
Patient Testimonials
“These research studies have continued to validate our commercial strategy, campaign, and tactics. Beyond the quantitative aspects, we are pleased to see the increasing preference for GIMOTI’s novel nasal route of administration versus traditional oral treatment methods. This observation reinforces our commitment to redefining the gastroparesis treatment landscape,” commented David Gonyer, R.Ph., Evoke Pharma President and CEO. “We continue to hear from patients and physicians about the benefits of GIMOTI and are actively capturing their feedback in market research and testimonial videos.”
Patient testimonial video: https://www.gimotirx.com/
“Diabetic gastroparesis can be difficult to treat given the disease itself can limit effectiveness of oral treatments. Orally administered medications can be blocked by the faulty stomach or vomited due to the symptoms often experienced by patients,” stated Dr. Fred C. Fowler, M.D., gastroenterologist and founding member of Carolina Digestive Health Associates in Charlotte, NC. ”Having a non-oral alternative like GIMOTI allows rapid delivery of a medication that bypasses the stomach to lessen symptoms such as abdominal pain, nausea and vomiting.”
GIMOTI Coverage
Evoke and Eversana continue to introduce the benefits of GIMOTI to various public and private insurers. Recently, GIMOTI has been added to the New York State Medicaid program for coverage requiring only proof of diabetes diagnosis.
“We continue to make strides across many aspects of commercialization such as brand awareness, patient successes and insurer coverage,” added Chris Quesenberry, GIMOTI Chief Commercial Officer. “We look forward to capitalizing on this information and encouraging providers to prescribe GIMOTI for appropriate patients to alleviate the symptoms associated with diabetic gastroparesis.”
GIMOTI® Patient Corner (Multimedia)
Since we introduced GIMOTI to the market in 2020, we have proactively gathered patient testimonials about their experience with GIMOTI and the difference it is making for them and their families. We encourage you to view a few real-life patient testimonials on GIMOTI and its game-changing effects: https://www.gimotirx.com/.
